Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

被引：0
|
作者：
Nils von Hentig
Brenda Dauer
Annette Haberl
Stefan Klauke
Thomas Lutz
Schlomo Staszewski
Sebastian Harder
机构：
[1] Johann Wolfgang Goethe University,Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology
[2] JohannWolfgang Goethe University Hospital Frankfurt,Medical HIV
[3] Infektiologicum Frankfurt,Treatment and Research Unit
来源：
European Journal of Clinical Pharmacology | 2007年 / 63卷
关键词：
HAART; Drug-drug interaction; TDM; Atazanavir; Tenofovir-DF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
    Veldkamp, AI
    van Heeswijk, RPG
    Mulder, JW
    Meenhorst, PL
    Schreij, G
    van der Geest, S
    Lange, JMA
    Beijnen, JH
    Hoetelmans, RMW
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 27 (04) : 344 - 349
  • [22] A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
    Spagnuolo, Vincenzo
    Galli, Laura
    Poli, Andrea
    Bigoloni, Alba
    Fumagalli, Luca
    Gianotti, Nicola
    Nozza, Silvia
    Ferrari, Davide
    Locatelli, Massimo
    Lazzarin, Adriano
    Castagna, Antonella
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 477 - 479
  • [23] Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients
    Mallolas, J.
    Sarasa, M.
    Nomdedeu, M.
    Soriano, A.
    Lopez-Pua, Y.
    Blanco, J. L.
    Martinez, E.
    Gatell, J. M.
    HIV MEDICINE, 2007, 8 (02) : 131 - 134
  • [24] Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir
    Viglietti, Denis
    Verine, Jerome
    De Castro, Nathalie
    Scemla, Anne
    Daudon, Michel
    Glotz, Denis
    Pillebout, Evangeline
    ANTIVIRAL THERAPY, 2011, 16 (01) : 119 - 121
  • [25] Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study
    Blanco, Jose L.
    Rojas, Jhon
    de Lazzari, Elisa
    Inciarte, Alexy
    Subirana, Mar
    Callau, Pilar
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    Mallolas, Josep
    de la Mora, Lorena
    Torres, Berta
    Gonzalez-Cordon, Ana
    Martinez, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (07) : 1974 - 1979
  • [26] Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily
    Elion, Richard
    Cohen, Calvin
    Ward, Douglas
    Ruane, Peter
    Ortiz, Roberto
    Reddy, Y. Sunila
    Ebrahimi, Ramin
    McColl, Damian
    Kearney, Brian
    Fisher, Alvan
    Flaherty, John
    HIV CLINICAL TRIALS, 2008, 9 (04): : 213 - 224
  • [27] Lack of interact-ion between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients
    Ruxrungtham, K
    Boyd, M
    Bellibas, SE
    Zhang, XP
    Dorr, A
    Kolis, S
    Kinchelow, T
    Buss, N
    Patel, IH
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (07): : 793 - 802
  • [28] Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults
    Lamorde, Mohammed
    Walimbwa, Stephen
    Byakika-Kibwika, Pauline
    Katwere, Michael
    Mukisa, Lillian
    Sempa, Joseph B.
    Else, Laura
    Back, David J.
    Khoo, Saye H.
    Merry, Concepta
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (05) : 1482 - 1486
  • [29] Ritonavir-boosted darunavir:: a powerful option for treatment-experienced HIV-1-infected patients
    Menendez-Arias, Luis
    Matamoros, Tania
    Alvarez, Mar
    FUTURE VIROLOGY, 2008, 3 (05) : 423 - 434
  • [30] Co-administered ritonavir and atazanavir but not demographic parameters or the pharmaceutical formulation influence steady-state population pharmacokinetics of saquinavir in HIV-1 infected adults
    von Hentig, N.
    Staszewski, S.
    Loetsch, J.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 : 95 - 95
12345